

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

BIO KEY INTERNATIONAL INC

Form: 4

Date Filed: 2019-04-01

Corporate Issuer CIK: 1019034

© Copyright 2019, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB A	PPROVAL
OMB Number:	3235-0287
Estimated average	burden hours
per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type R	Responses)															
Name and Address of Reporting Person [*] Knook Pieter Cornelis				Issuer Name and Ticker or Trading Symbol BIO KEY INTERNATIONAL INC [BKYI]						Relationship of Reporting Person(s) to Issuer						
(Last) (Middle) C/O BIO-KEY INTERNATIONAL, INC., 3349 HIGHWAY 138, BUILDING A, SUITE E				Date of Earliest Transaction (Month/Day/Year) 03/28/2019							Officer (give titl	e below)		(specify below)		
(Street) WALL, NJ 07719				4. If Amendment, Date Original FiledMonth/Day/Year)						Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)		(State)	(Zip)			Tal	ole I - N	on-D	erivative s	Securitie	s Acq	uired, Disposed o	of, or Benef	ficially Owned		
(Instr. 3) Date		2. Transaction Date (Month/Day/Yea	ar) any	emed tion Date, i	if Code (Instr	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				curities Beneficially Owned ted Transaction(s)		Ownership Form:	Beneficial	
				(Month/D	ау/теа		ode	٧	Amount	(A) or (D)	Price				Direct (D) or Indirect (I) (Instr. 4)	Ownershi (Instr. 4)
Common St	ock		03/28/2019				Α		368 (1)	Α	\$0	11,494			D	
			Table II	- Derivative			fo O cquired	rm a MB o	are not requestion of the control of	uired to mber. or Bene	respo	ollection of informulation of unless the formulation of the control of the contro				1474 (9-02
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year) any (Month/Day.		(Instr. 8) Sear) A		Number of erivative ecurities equired (A) or sposed of (D) estr. 3, 4, and 5)		and (Mo	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following	10. Ownership Form of Derivative Security: Direct (D)	Beneficial
				Code	V	(A)	(D)	Da ^s Exe	te E ercisable D	xpiration ate		Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)	
Reportin	ng Ownei	's														
Repo	orting Owner N	ame / Address		Relationsh	r e		1									
Director				10% Owner	Office	r Othe	r									

Damantina Caman Nama / Adduses	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Knook Pieter Cornelis C/O BIO-KEY INTERNATIONAL, INC. 3349 HIGHWAY 138, BUILDING A, SUITE E WALL, NJ 07719	Х						

Signatures

/s/ Pieter C. Knook	04/01/2019
-Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares issued to the Reporting Person on March 28, 2019 under the Issuer's 2015 Equity Incentive Plan in payment of board committee meeting attendance fees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burde	n hours						
per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Responses)															
1. Name and Address of Reporting Person- Knook Pieter Cornelis						_	•			Relationship of Reporting Person(s) to Issuer (Check all applicable) X. Director. 10% Owner. 10% Owner.					
(Last) (First) (Middle) C/O BIO-KEY INTERNATIONAL, INC., 3349 HIGHWAY 138, BUILDING A, SUITE E			Date of Earliest Transaction (Month/Day/Year) 03/28/2019								e below)				
(Street) WALL, NJ 07719				4. If Amendment, Date Original FiledMonth/Day/Year)								Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
					quired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea	ar) any	(Instr. 8)			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ownership of Form:	Beneficial		
			(МОПШ/Вау/Те	Code	,	V	Amount	(A) or (D)	Price	9			. ,	Ownership (Instr. 4)	
tock		03/28/2019		Α			368 (1)	Α	\$0	11,494			D		
port on a separa	te line for each class	s of securities ben	eficially owned dir	ectly or indire	ctly.										
			,	•	form	n aı	re not req	uired to						474 (9-02)	
		Table II		•						y Owned					
2.	3. Transaction	3A. Deemed	14 + 10 10	. Number of	Τ.		ate Exerc	io o bilo		le and Amount of	O Dring of	9. Number of	10.	11. Nature	
	er Cornelis EY INTERNA 138, BUILDIN 07719 rity	er Cornelis EY INTERNATIONAL, INC., (138, BUILDING A, SUITE E (Street) 107719 (State) rity	er Cornelis (First) (Middle)	BIO KEY INTEL (First) (Middle) 3. Date of Earliest 03/28/2019 138, BUILDING A, SUITE E (Street) 4. If Amendment, Description Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Dort on a separate line for each class of securities beneficially owned directions are considered as a constant of the control of the c	BIO KEY INTERNATIONAL (First) (Middle) 3. Date of Earliest Transaction (No.3/28/2019) 3. Date of Earliest Transaction (No.3/28/2019) 4. If Amendment, Date Original First (Street) 77719 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) Code (Instr. 8) Code or or on a separate line for each class of securities beneficially owned directly or indirectly or	BIO KEY INTERNATIONAL IN C., 3349 138, BUILDING A, SUITE E (Street) (State) (State) (State) (State) (State) (State) (Zip) (State) (Zip) (State) (Zip) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Code (Instr. 8) Code (Instr. 8) Code Code (Instr. 8) Per form form OM Table II - Derivative Securities Acquired, I	BIO KEY INTERNATIONAL INC. (First) (First) (First) (SY INTERNATIONAL, INC., 3349 138, BUILDING A, SUITE E (Street) (State) (State) (State) (Zip) Table I - Non-Double (Instr. 8) (Month/Day/Year) (Month/Day/Year) (Code (Instr. 8) Persor form at OMB c Table II - Derivative Securities Acquired, Disp	BIO KEY INTERNATIONAL INC [BKYI] (First) (Middle) (Street) 3. Date of Earliest Transaction (Month/Day/Year) (Month/Day/Year) (Street) 4. If Amendment, Date Original FiledMonth/Day/Year) (State) (Zip) Table I - Non-Derivative Street) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	BIO KEY INTERNATIONAL INC [BKYI] (First) (Middle) (SY INTERNATIONAL, INC., 3349 (138, BUILDING A, SUITE E (Street) 4. If Amendment, Date Original FiledMonth/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Execution Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A) or Disposed of (Instr. 8) (Instr. 3, 4 and 5) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (A) or Disposed of (Instr. 8) (BY INTERNATIONAL INC (Month/Day/Year) (Instr. 8) (Instr. 8) (A) or Disposed of (Instr. 8) (Instr. 8) (A) or Disposed of (Instr. 8) (Instr. 8) (A) or Disposed of (Instr. 8) (Instr. 8) (BY INTERNATIONAL INC (Month/Day/Year) (Instr. 8)	BIO KEY INTERNATIONAL INC [BKYI] (First) (Middle) (SY INTERNATIONAL, INC., 3349 138, BUILDING A, SUITE E (Street) 4. If Amendment, Date Original FiledMonth/Day/Year) (State) (State) (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A) or Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Original FiledMonth/Day/Year) (A) or Disposed of (D) (Instr. 8) (B) Order of the Control of th	BIO KEY INTERNATIONAL INC [BKYI] 3. Date of Earliest Transaction (Month/Day/Year) 03/28/2019 4. If Amendment, Date Original FiledMonth/Day/Year) (Street) 4. If Amendment, Date Original FiledMonth/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of Date (Month/Day/Year) (Month/Da	BIO KEY INTERNATIONAL INC [BKYI] (Chec (First) (Middle) (Street) (Street) (Street) (State) (Zip) (State) (Zip) (Month/Day/Year) (State) (Zip) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (State) (Zip) (Month/Day/Year) (M	BIO KEY INTERNATIONAL INC [BKYI] (Check all applicable X_Director 10% COMB (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 03/28/2019 4. If Amendment, Date Original FiledMonth/Day/Year) 6. Individual or Joint/Group Filing/Check Applic X_Form filed by One Reporting Person Form filed by More than One Reporting Person Form filed by One Reporting Person Form filed by More than One Reporting Person Form filed	BIO KEY INTERNATIONAL INC [BKYI] (Check all applicable) Y INTERNATIONAL, INC., 3349 138, BUILDING A, SUITE E (Sireet) 4. If Amendment, Date Original FiledMonth/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 77719 (State) 2. Transaction Date (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) A 368 1 A \$0 11,494 Devort on a separate line for each class of securities beneficially owned directly or indirectly. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired to respond unless the form displays a currently valid OMB control number.	

Reporting Owners

Deposition Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Knook Pieter Cornelis C/O BIO-KEY INTERNATIONAL, INC. 3349 HIGHWAY 138, BUILDING A, SUITE E WALL, NJ 07719	Х						

Signatures

/s/ Pieter C. Knook	04/01/2019
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares issued to the Reporting Person on March 28, 2019 under the Issuer's 2015 Equity Incentive Plan in payment of board committee meeting attendance fees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.